BRAF is altered in 1.12% of germ cell tumor patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for germ cell tumor, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and germ cell tumor as inclusion criteria, 2 are phase 2 (1 open) [3].

BRCA1 is altered in 0.68% of germ cell tumor patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is altered in 1.76% of germ cell tumor patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is altered in 0.14% of germ cell tumor patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND2 is altered in 15.45% of germ cell tumor patients [2].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND3 is altered in 0.27% of germ cell tumor patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND3 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE1 is altered in 0.54% of germ cell tumor patients [2].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCNE2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK4 is altered in 0.54% of germ cell tumor patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK6 is altered in 0.55% of germ cell tumor patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1A is altered in 0.28% of germ cell tumor patients [2].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1B is altered in 18.98% of germ cell tumor patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN2A is altered in 0.87% of germ cell tumor patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

ERBB2 is altered in 0.75% of germ cell tumor patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains ERBB2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

KRAS is altered in 22.8% of germ cell tumor patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].

MYCN is altered in 1.76% of germ cell tumor patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and germ cell tumor as inclusion criteria, 1 is no phase specified (1 open) [3].

RB1 is altered in 0.5% of germ cell tumor patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [3].